Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-1816-2026

Cytal Wound Matrix 2-Layer 5x5 cm. Product ID: WSM0505. Recall

Cytal Wound Matrix 2-Layer 5x5 cm. Product ID: WSM0505.

FDA recall Class II

Ongoing

FDA lists this Class II recall for Cytal Wound Matrix 2-Layer 5x5 cm. Product ID: WSM0505.. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-1816-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Mar 19, 2026
FDA report date
Apr 22, 2026
Quantity in commerce
148 units
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

Cytal Wound Matrix 2-Layer 5x5 cm. Product ID: WSM0505.

Affected model & UDI checker

Search the exact identifiers published for Z-1816-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
Not specifiedCytal Wound Matrix 2-Layer 5x5 cm. Product ID: WSM0505.Check source notice00386190001431
FDA code information

Product ID: WSM0505. UDI-DI: 00386190001431. Lot Numbers: 7579683, 7583933, 7583891, 7583935, 7594266, 7594286, 7593011.

View the original FDA recall notice

Why was this product recalled?

Increased rate of out-of-specification endotoxin results.

What actions did Integra LifeSciences Corp. (NeuroSciences) take?

Integra LifeSciences notified consignees on about 03/19/2026 via letter. Consignees were instructed to identify any affected units on hand and remove them immediately from service and quarantine them, complete and return the Acknowledgment Form and arrange for the return of affected units. Consignees were also instructed to forward to all affected personnel who utilize the product so they are aware of the recall and can identify any affected product that may remain in clinical areas. Distributors were instructed to identify any affected units on hand and remove them immediately from service and quarantine them, complete and return the Acknowledgment Form and arrange for the return of affected units. Distributors were also instructed to check customer traceability records and notify them if they have any shipments with affected units. They requested to modify the acknowledgement form to provide to customers, collect completed response forms and provide those numbers in the distributor reply form. Integra LifeSciences sent a second notification letter on about 03/20/2026, which updated the lot numbers affected. Consignees were asked to disregard the previous letter and replace it with the updated one. Directions for consignees and distributors did not change.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology